Alector grants Genentech exclusive rights to Parkinson's treatment AL050 in deal worth up to $1.17bn

Alector granted Genentech exclusive rights to develop and commercialize AL050, an investigational GCase enzyme replacement therapy for Parkinson's, in a deal worth up to $1.17bn including $100m cash upfront.

Detected & updated continuously · Source: Nebula